Skip to main content

Table 3 Pain and physical functioning before (baseline) and after (1-, 2- and 6-month follow-ups) repeated tender-point injections with active substance (GRA) or control substance (CTR), in 40 patients with myofascial temporomandibular disorders

From: Repeated tender point injections of granisetron alleviate chronic myofascial pain - a randomized, controlled, double-blinded trial

 

Baseline

1 month

2 months

6 months

 

GRA

CTR

GRA

CTR

GRA

CTR

GRA

CTR

Pain variables

n = 20

n = 20

n = 20

n = 18

n = 16

n = 8

n = 10

n = 5

 Pain intensity

52 (29)

57 (24)

29 (41)a

29 (40)

32 (30)ab

36 (25)

24 (35)ab

34 (31)

  Responders; ≥30 %

-

-

16c

11

12c

6

7c

2

  Responders; ≥50 %

-

-

8

8

7d

4

5d

1

 Pain area

100

100

62.4 (95.9)e

76.5 (99.9)

62.9 (105.6)e

74.8 (149.1)

44.5 (141.3)e

81.2 (189.3)

Physical functioning

n = 19

n = 19

n = 20

n = 17

n = 16

n = 8

n = 10

n = 5

 GCPS

        

  Grade 0

5

12

8

11

7

6

6

2

  Grade I

4

1

6

1

1

1

1

2

  Grade II

9

4

4

2

3

1

1

1

  Grade III

0

1

1

3

3

0

2

0

  Grade IV

1

1

1

0

1

0

0

0

 JDC

        

  Score (0–12)

3 (5)

2 (4)

3 (5)

2 (4.5)

3 (4)

2 (5.5)

3 (5)

1 (3.5)

 MVO

        

  Without pain (mm)

41.1 (9.3)

44.0 (10.9)

42.9 (9.3)

47.6 (9.4)

43.3 (9.4)*

46.9 (9.4)

47.2 (10.8)*

46.1 (6.2)

  With pain (mm)

49.7 (7.5)

52.8 (10.0)

47.9 (8.2)

52.8 (9.5)

49.2 (7.5)

51.3 (9.8)

49.3 (10.5)

50.4 (7.5)

  1. The table presents median (IQR) weekly pain intensity (VAS; 0–100 mm), number of responders to treatment (≥30 % and ≥50 % decrease in pain intensity), median (IQR) pain area (%) normalized to baseline, distribution of physical functioning assessed with the Graded Chronic Pain Scale (GCPS) and median (IQR) limitation in jaw function assessed with the Jaw Disability Checklist (JDC) as well as the mean (SD) maximum voluntary mouth opening capacity (MVO) with and without pain
  2. GRA Granisetron (Kytril®; 1 mg/mL, Roche, Stockholm, Sweden), CTR control substance (isotonic saline (NaCl); 0.9 mg/mL, Fresenius Kabi, Uppsala, Sweden), IQR Interquartile range (the 75th percentile minus the 25th percentile), SD Standard deviation, VAS Visual Analogue Scale, AU Arbitrary units
  3. Physical functioning: GCPS: Grade 0 = no disability; Grade I = low disability and low intensity pain; Grade II = low disability and high intensity pain; Grade III = high disability and moderately limiting; Grade IV = high disability and severely limiting
  4. aSignificant decrease compared to baseline (Dunn’s test: 1 month: P = 0.031; 2 months: P = 0.008; 6 months: P = 0.007. bSignificant difference compared to the CTR-group (Mann–Whitney U-test; 2-months: P = 0.009; 6-months: P = 0.031). cSignificant difference compared to the CTR-group (χ 2-test; P < 0.001)
  5. dSignificant difference compared to the CTR-group (χ 2-test; 2 months: P = 0.027; 6 months: P < 0.001). eSignificant difference (Holm Sidak’s test; 1 month: P = 0.039; 2 months: P = 0.039; 6 months: P = 0.042). *Significant difference compared to baseline (Holm Sidak’s test; P < 0.001), but not in the CTR-group
Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us